Menu Search
Equities

Karyopharm Therapeutics Inc

25K:MUN

Karyopharm Therapeutics Inc

Actions
  • Price (EUR)1.04
  • Today's Change0.00 / 0.00%
  • Shares traded3.50k
  • 1 Year change-71.25%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024 07:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

  • Revenue in USD (TTM)146.03m
  • Net income in USD-143.10m
  • Incorporated2008
  • Employees325.00
  • Location
    Karyopharm Therapeutics Inc85 Wells AveNEWTON CENTER 02459-3298United StatesUSA
  • Phone+1 (617) 658-0600
  • Fax+1 (302) 655-5049
  • Websitehttps://karyopharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.